[Correspondence] Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma – Authors' reply

We thank Bhumesh Tyagi and colleagues for their comments. INTERACT-ION was designed to show the feasibility and preliminary efficacy of induction with modified docetaxel, cisplatin, and fluorouracil (mDCF) plus ezabenlimab then intensity-modulated radiotherapy with involved-node chemoradiotherapy (INRT) in patients with locally advanced squamous cell anal carcinoma (SCAC).1 We showed the value of this novel induction regimen, with 38 (75%) of…